BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr
The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
(BBIO) on Thursday reported a loss of $56.The Palo Alto, California-based company said it had a loss of 42 cents per share.
Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.
BridgeBio Pharma (BBIO) has an average rating of buy and mean price target of $111, according to ana
BridgeBio (BBIO) Phase 3 encaleret results in ADH1 show symptom and bone-health gains; FDA priority review decision May 2027—read key investor takeaways.
Here is how to initiate a holding in the name with a covered call order.
Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Mas
This is the newest page. Registered accounts read further back.